Acurian's Database Eclipses 50 Million Patients; Company Extends Exclusivity for Clinical Trial Recruitment.

HORSHAM, Pa. -- Acurian, Inc., a leading provider of patient recruitment solutions, announced today that its opted-in database of self-reported chronic disease sufferers has surpassed the 50 million patient mark. In addition, the company reported that it has extended by five years its exclusive agreement with the largest aggregator of self-reported ailment data for the purpose of clinical trial recruitment.

"The growth of our patient database mirrors that of our business," said Rick Malcolm, PhD, Acurian's CEO. "In the past two years, we've seen our patient recruitment projects increase significantly as customers have requested more randomizations for larger studies consisting of multiple protocols across hundreds of sites."

Acurian's primary approach to patient recruitment is through its patient database, which enables the company to contact potential trial participants directly through postal and/or email communications. The database, started over 10 years ago, has grown both organically through the Acurian website, and strategically through partnerships with specialized health data aggregators, including the largest in North America.

"This year, we extended our exclusive partnership with the leading provider of self-reported health data," continued Malcolm. "No one but Acurian can leverage this data for the purposes of clinical trial patient recruitment. It represents a significant competitive advantage for us, and a significant enrollment advantage for sponsors who choose to work with Acurian."

The company stated that the database offers a more predictable recruitment and enrollment strategy for many indications in CNS, cardiovascular, endocrinology, inflammation and several other major therapeutic areas. Acurian also offers patient recruitment contracts predicated on its ability to meet specific recruitment milestones, including randomization.

About Acurian

Acurian is a leading full-service provider of clinical trial patient recruitment solutions for the life sciences industry. Through its proprietary patient panel of over 50 million patients, centralized advertising capabilities, and a fully hosted enrollment management technology platform, Acurian is able to identify, contact, prescreen, and refer patients into clinical trials, all while supporting investigator sites with services to maximize the randomization potential of every referred patient. Since 1998, Acurian has supported over 300 protocols for more than 60 companies. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures. Please visit www.acurian.com.